[HTML][HTML] A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

…, P Therasse, MJ Palmer, JL Pater - … England Journal of …, 2003 - Mass Medical Soc
Background In hormone-dependent breast cancer, five years of postoperative tamoxifen
therapy — but not tamoxifen therapy of longer duration — prolongs disease-free and overall …

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17

…, DA Cameron, MJ Palmer, JL Pater - Journal of the …, 2005 - academic.oup.com
Background: Most recurrences in women with breast cancer receiving 5 years of adjuvant
tamoxifen occur after 5 years. The MA.17 trial, which was designed to determine whether …

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.

E Rapp, JL Pater, A Willan, Y Cormier… - Journal of Clinical …, 1988 - ascopubs.org
The survival benefit of combination chemotherapy to patients with advanced non-small-cell
carcinoma of the lung (NSCLC) is controversial. To study this question, the National Cancer …

Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models

T Voskoglou-Nomikos, JL Pater, L Seymour - Clinical cancer research, 2003 - AACR
Purpose: We looked at the value of three preclinical cancer models, the in vitro human cell
line, the human xenograft, and the murine allograft, to examine whether they are reliable in …

Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical …

N Murray, P Coy, JL Pater, I Hodson… - Journal of Clinical …, 1993 - ascopubs.org
PURPOSE The importance of the timing of thoracic irradiation (TI) in the combined modality
therapy of limited-stage small-cell lung cancer (SCLC) was assessed in a randomized trial. …

Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis

…, N Arber, B Levin, CL Meinert, B Martin, JL Pater… - Circulation, 2008 - Am Heart Assoc
Background— Observational studies and randomized trials have reported increased
cardiovascular risk associated with cyclooxygenase-2 inhibitors. Prior placebo-controlled …

Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?

KWL Yee, JL Pater, L Pho, B Zee… - Journal of Clinical …, 2003 - ascopubs.org
Purpose: To evaluate the enrollment of older patients (≥ 65 years) in Canadian cancer
treatment trials and compare accrual of older patients in Canada and the United States. Patients …

Assessment of quality of life in MA. 17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women

TJ Whelan, PE Goss, JN Ingle, JL Pater… - Journal of Clinical …, 2005 - ascopubs.org
Purpose To evaluate the impact of letrozole compared with placebo after adjuvant tamoxifen
on quality of life (QOL) in the MA.17 trial. Methods Patients completed the Short Form 36-…

[PDF][PDF] Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen

PE Goss, JN Ingle, JL Pater, S Martino… - Journal of Clinical …, 2008 - Citeseer
Purpose The National Cancer Institute of Canada Clinical Trials Group MA. 17 trial examined
the efficacy of letrozole (LET) started within 3 months of 5 years of adjuvant tamoxifen in …

Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC. 15)

…, C Leong, L Mulroy, C Smith, J Wright, JL Pater - International Journal of …, 2002 - Elsevier
Purpose : This multi-institutional Phase III randomized study compared 10 Gy single-fraction
radiotherapy (RT) with 20 Gy in five fractions in the palliation of thoracic symptoms from lung …